Russian Drug Production In 1996

8 April 1997

Russian drug production value in 1995 is put at 136.8 billion roubles($23.8 million) in 1996, or 96.6% of 1995's figure. Volume output rose 2.8%, mainly led by the Leksredstva, Oktyabr, Voronezhkhimfarm and Tomsk KhFZ enterprises, whose share in total output was near 37%. Their volume rose 63%, 27.5%, 7.2% and 0.7% respectively.

Patchy reporting of production throughout the Federation means that no entirely clear picture emerges, but a fall in output was reported at 35% enterprises and a rise at 26 others. Funding shortages and a fall in demand partly explained some of the more dramatic output declines, eg those at Tatkhimfarmpreparaty in Kazan (-89%) and Miskhimfarmpreparaty (-78%).

Ampoule production fell 1.1%, and a fall-off in demand was reported for drugs in 1ml ampoules. Production of pharmaceutical substances fell 76%, matched by a considerable fall in product ranges. Tonnage of raw drugs manufactured was 76% of 1995 output, and manufacture of synthetic substances and raw vitamins fell to 2,840 tonnes of the former and 964.5 tonnes of the latter, down to 76% and 63.7% of 1995 levels respectively.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight